Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Open accessThe DOI matches its Crossref record; 148 of the 149 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a disorder that causes degeneration of the cells in the brain and it is the main cause of dementia, which is characterized by a decline in thinking and independence in personal daily activities. AD is considered a multifactorial disease: two main hypotheses were proposed as a cause for AD, cholinergic and amyloid hypotheses. Additionally, several risk factors such as increasing age, genetic factors, head injuries, vascular diseases, infections, and environmental factors play a role in the disease. Currently, there are only two classes of approved drugs to treat AD, including inhibitors to cholinesterase enzyme and antagonists to N-methyl d-aspartate (NMDA), which are effective only in treating the symptoms of AD, but do not cure or prevent the disease. Nowadays, the research is focusing on understanding AD pathology by targeting several mechanisms, such as abnormal tau protein metabolism, β-amyloid, inflammatory response, and cholinergic and free radical damage, aiming to develop successful treatments that are capable of stopping or modifying the course of AD. This review discusses currently available drugs and future theories for the development of new therapies for AD, such as disease-modifying therapeutics (DMT), chaperones, and natural compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is characterized by neurodegeneration due to neuronal cell death, starting in the entorhinal cortex of the hippocampus, primarily affecting individuals aged 65 and older [1].”
From Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For ADs, precision medicine focuses on genetic and biomarker analysis to improve therapy approaches, risk assessment, and diagnosis.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They may also be the cause of neuroinflammation by activating microglia and producing inflammatory cytokines.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Early in AD progression, damage to neuronal connections occurs primarily in the medial temporal lobe and neocortical areas (Figure 2B) [42,43].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“The first disease-modifying medication for AD is a recombinant monoclonal antibody called aducanumab, also known by the brand name Aduhelm. It targets amyloid beta specifically [37]. It functions by lowering the quantity of amyloid deposits or brain plaques [130,131].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430 · cited 2×
“At present, there is no cure for Alzheimer’s disease, although there are available treatments that just improve the symptoms [6,7].”
BackgroundRetractedTacrine for Alzheimer's disease
Qizilbash, N., Birks, J., López Arrieta, J., Lewington, S., & Szeto, S. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000202 · Cited by 82 · cited 1×
“Later on, several AChEIs were introduced, such as donepezil (2, Figure 4), rivastigmine (3, Figure 4), and galantamine (4, Figure 4), and are currently in use for the symptomatic treatment of AD [34,97,102,103].”
BackgroundRetractedLi, J.-G., Chiu, J., & Praticò, D. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0364-x · Cited by 51 · cited 1×
“The study showed that a significant reduction of the Aβ peptide and tau neuropathology (soluble, insoluble, and phosphorylated tau) was associated with overexpression of VPS35, in addition to a reduction in neuroinflammation and ameliorating synaptic dysfunction [142].”
BackgroundRetractedRETRACTED ARTICLE: VPS35 regulates tau phosphorylation and neuropathology in tauopathy
Vagnozzi, A. N., Li, J.-G., Chiu, J., Razmpour, R., Warfield, R., Ramirez, S. H., & Praticò, D. (2021) · Molecular Psychiatry · doi:10.1038/s41380-019-0453-x · Cited by 36 · cited 1×
“A loss of retromer’s function results in the downregulation of VPS35, which can increase Aβ formation, induce cognitive impairments, and cause synaptic dysfunction, which is reported in AD patients [140,141].”
BackgroundRetractedMcKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · cited 1×
“All of these symptoms can start from age 40–90, with the absence of any systemic or brain diseases, (2) possible Alzheimer’s disease can be applied in the absence of neurologic, psychiatric disorders, and the presence of another illness like systemic or brain disorder, but they are not the primary cause of dementia, a…”
BackgroundMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“ApoEε4 plays an important role in Aβ deposition as a senile plaque and causes cerebral amyloid angiopathy (CAA), which is known as a marker for AD [59].”
BackgroundNeuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310 · cited 1×
“These changes also appear in normal aging, which makes it difficult to distinguish the cases in early AD [43,44].”
BackgroundThe cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Research works printed but not linked: 4
- Kumar A. Sidhu J. Goyal A. Alzheimer Disease StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK499922/ (accessed on 8 December 2020)
- Singh R. Sadiq N.M. Cholinesterase Inhibitors StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK544336/ (accessed on 8 December 2020)
- Kuns B. Rosani A. Varghese D. Memantine StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK500025/ (accessed on 8 December 2020)
- Kumar A. Sharma S. Donepezil StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK513257/ (accessed on 8 December 2020)
Cited by
Items 101–200 of 1,010
Role of SNAREs in Neurodegenerative Diseases
Margiotta, A. (2021) · Cells · doi:10.3390/cells10050991 · Cited by 78
“AD can be classified as late-onset (LOAD), sporadic (SAD) or early-onset (EOAD) and familial (FAD).”
BackgroundInfluentialPuri, D., Nalbalwar, S. L., Nandgaonkar, A. B., Gawande, J. P., & Wagh, A. E. (2022) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2022.104439 · Cited by 81
Subramanian, A., Tamilanban, T., Alsayari, A., Ramachawolran, G., Wong, L. S., Sekar, M., Gan, S. H., Subramaniyan, V., Chinni, S. V., Rani, N. N. I. M., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1094351 · Cited by 73
Mitochondrial dysfunction in Alzheimer's disease: Guiding the path to targeted therapies
Percy, K. C. M., Liu, Z., & Qi, X. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00525 · Cited by 80
“As the disease progresses to its later stages, symptoms include signi fi cant cognitive decline, dif fi culty communicating, and the need for full-time assistance with daily personal care, which places a heavy burden on caregivers and family members [2].”
Akyuz, E., Arulsamy, A., Aslan, F. S., Sarisözen, B., Guney, B., Hekimoglu, A., Yilmaz, B. N., Retinasamy, T., & Shaikh, M. F. (2025) · Molecular Neurobiology · doi:10.1007/s12035-024-04333-y · Cited by 69
“…development of disease modifying therapies (DMTs) that have been able to target the underlying pathophysiology of the disease and prevent the disease progression at an early stage, with the aim of obtaining an enduring clinical benefit in improving the life for Alzheimer’s disease patients [310].”
Dynamics of Choline-Containing Phospholipids in Traumatic Brain Injury and Associated Comorbidities
Javaid, S., Farooq, T., Rehman, Z., Afzal, A., Ashraf, W., Rasool, M. F., Alqahtani, F., Alsanea, S., Alasmari, F. F., Alanazi, M. M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111313 · Cited by 72
“The amyloid precursor protein (APP) has a key role in the progression of AD, as this protein undergoes the sequential proteolytic cleavages to yield β-amyloid peptides (Aβ) [90].”
BackgroundTherapeutic potential of natural molecules against Alzheimer's disease via SIRT1 modulation
Zhang, M., & Tang, Z. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114474 · Cited by 74
Anti-Alzheimer activity of new coumarin-based derivatives targeting acetylcholinesterase inhibition
Kamel, N. N., Aly, H. F., Fouad, G. I., El‐Karim, S. S. A., Anwar, M. M., Syam, Y. M., Elseginy, S. A., Ahmed, K. A., Booles, H. F., Shalaby, M. B., et al. (2023) · RSC Advances · doi:10.1039/d3ra02344c · Cited by 71
Liu, D., Zhang, H., Wang, Y., Liu, W., Yin, G., Wang, D., Li, J., Shi, T., & Wang, Z. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114044 · Cited by 68
Fang, C., Hernandez, P., Liow, K. K., Damiano, E., Zetterberg, H., Blennow, K., Feng, D., Chen, M., & Maccecchini, M. L. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.84 · Cited by 69
“Although APP and its downstream products (Aβ oligomers, c-terminus peptide, and amyloid plaques), and tau neurofibrillary tangles have been well documented to be culprits of AD (3), other misfolded proteins are also suggested to be part of the equation.”
BackgroundLipids uniquely alter the secondary structure and toxicity of amyloid beta 1–42 aggregates
Zhaliazka, K., Matveyenka, M., & Kurouski, D. (2023) · FEBS Journal · doi:10.1111/febs.16738 · Cited by 67
Khedraoui, M., Nour, H., Yamari, I., Abchır, O., Errougui, A., & Chtita, S. (2023) · Chemical Physics Impact · doi:10.1016/j.chphi.2023.100361 · Cited by 67
Alzheimer’s disease: a review on the current trends of the effective diagnosis and therapeutics
Manap, A. S. A., Almadodi, R., Sultana, S., Sebastian, M. G., Kavani, K. S., Lyenouq, V. E., & Shankar, A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1429211 · Cited by 84
Cell-type-directed network-correcting combination therapy for Alzheimer’s disease
Li, Y., Serras, C. P., Blumenfeld, J. R., Xie, M., Hao, Y., Deng, E., Chun, Y. Y., Holtzman, J., An, A., Yoon, S. Y., et al. (2025) · Cell · doi:10.1016/j.cell.2025.06.035 · Cited by 74
The Histaminergic System in Neuropsychiatric Disorders
Cheng, L., Liu, J.-Y., & Chen, Z. (2021) · Biomolecules · doi:10.3390/biom11091345 · Cited by 49
The Oral–Gut Microbiome–Brain Axis in Cognition
Adil, N. A., Omo-erigbe, C., Yadav, H., & Jain, S. (2025) · Microorganisms · doi:10.3390/microorganisms13040814 · Cited by 69
“Individuals with MCI are at high risk of further progression to more severe cognitive impairment [4].”
Althobaiti, N. A. (2025) · Behavioural Brain Research · doi:10.1016/j.bbr.2024.115212 · Cited by 64
Single-Cell RNA-Sequencing: Astrocyte and Microglial Heterogeneity in Health and Disease
Spurgat, M. S., & Tang, S. (2022) · Cells · doi:10.3390/cells11132021 · Cited by 69
“Although there is no cure for AD, there are currently several treatment options available that can be used to manage the symptoms, including cholinesterase inhibitors and antagonists of N-methyl-D-aspartate (NMDA) receptors [37].”
BackgroundAkhtar, A., Rad, V. F., Moradi, A., Yar, M., & Bazzar, M. (2022) · Smart Materials in Medicine · doi:10.1016/j.smaim.2022.11.007 · Cited by 70
Villalonga-Rosso, E., Mosrin-Huaman, C., Normand, T., Girardin, C., Serrano, A., Žunar, B., Doudeau, M., Godin, F., Bénédetti, H., & Vallée, B. (2023) · Cells · doi:10.3390/cells12050805 · Cited by 65
Limantoro, J., de Liyis, B. G., & Sutedja, J. C. (2023) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-023-00751-2 · Cited by 243
“There is a significant presence of neuritic amyloid plaques, neurofibrillary tangles of tau protein, and enormous loss of neurons on individuals who experienced from memory impairment and emotional changes before dying, and the illness was defined as a severe cerebral cortex disease [1].”
BackgroundInfluentialLal, U., Chikkankod, A. V., & Longo, L. (2024) · Brain Sciences · doi:10.3390/brainsci14040335 · Cited by 66
LEADNet: Detection of Alzheimer’s Disease Using Spatiotemporal EEG Analysis and Low-Complexity CNN
Puri, D., Kachare, P. H., Sangle, S. B., Kirner, R., Jabbari, A., Al–Shourbaji, I., Abdalraheem, M. H. O., & Alameen, A. A. M. (2024) · IEEE Access · doi:10.1109/access.2024.3435768 · Cited by 78
“An early phase of AD known as mild The associate editor coordinating the review of this manuscript and approving it for publication was Nuno M. Garcia . cognitive impairment (MCI) affects 5-20% of older persons (age over 60) [2].”
BackgroundZebrafish and Medaka: Important Animal Models for Human Neurodegenerative Diseases
Wang, J., & Cao, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910766 · Cited by 67
New insight into protein glycosylation in the development of Alzheimer’s disease
Zhao, J., & Lang, M. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01617-5 · Cited by 70
“In addition, brain atrophy caused by loss of nerves, nerve cells, and synapses can also provide evidence for AD progression [1].”
BackgroundInfluentialHulse, J. P., & Bhaskar, K. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.805169 · Cited by 66
The Bioactivities of Phycocyanobilin from Spirulina
Li, Y. (2022) · Journal of Immunology Research · doi:10.1155/2022/4008991 · Cited by 81
“Regarding the pathogenesis of AD, two primary hypotheses were elucidated: (1) cholinergic and (2) amyloid [51, 52].”
Role of SUMOylation in Neurodegenerative Diseases
Mandel, N., & Agarwal, N. (2022) · Cells · doi:10.3390/cells11213395 · Cited by 70
Gut microbiota in neurological diseases: Melatonin plays an important regulatory role
Ahmadi, S., Taghizadieh, M., Mehdizadehfar, E., Hasani, A., Fard, J. K., Feizi, H., Hamishehkar, H., Ansarin, M., Yekani, M., & Memar, M. Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116487 · Cited by 67
Chen, J., Zhao, D., Yin, Y., Gui, L., Chen, X., Wang, X., Wang, P., Zuo, C., Lai, Z., Li, C., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002490 · Cited by 75
Cutuli, D., Decandia, D., Giacovazzo, G., & Coccurello, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914686 · Cited by 64
“To date, there is still no cure for AD and pharmacological approaches focus more on reducing symptoms using cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine, as well as N-methyl d-aspartate (NMDA) antagonists such as memantine [18].”
BackgroundPires, P. C., Paiva‐Santos, A. C., & Veiga, F. (2023) · Pharmaceuticals · doi:10.3390/ph16101424 · Cited by 69
“…being connected to increased mortality, with the person developing high levels of dependence, since aside from experiencing difficulty in remembering things, which worsens with time, patients also tend to lose their ability to communicate, as well as the awareness of their surroundings [36,38,39].”
BackgroundSharma, A., Rudrawar, S., Bharate, S. B., & Jadhav, H. R. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00630e · Cited by 70
“Therapeutic approaches for the treatment of AD”
Alzheimer’s disease and drug delivery across the blood–brain barrier: approaches and challenges
Iqbal, I., Saqib, F., Mubarak, Z., Latif, M. F., Wahid, M., Nasir, B., Shahzad, H., Sharifi-Rad, J., & Mubarak, M. S. (2024) · European Journal of Medical Research · doi:10.1186/s40001-024-01915-3 · Cited by 60
“Additionally, there are genetic variants, such as the ApoE4 allele, which cause significantly increased women’s risk of AD compared to men’s risk [54].”
BackgroundIntranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications
Taléns-Visconti, R., de Julián-Ortiz, J. V., Vila-Busó, O., Diez-Sales, O., & Nácher, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051399 · Cited by 59
“There were over 50 million ATD cases globally as of 2020 [4].”
BackgroundTao, D., Scully, R., Ash, G. I., Pei, Z., Gu, Y., Gao, Y., Cole, A. M., & Baker, J. S. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102120 · Cited by 64
Chen, Z., Wang, X., Du, S., Liu, Q., Xu, Z., Guo, Y., & Lin, X. (2024) · Chinese Medicine · doi:10.1186/s13020-024-00900-6 · Cited by 66
“AD is a neurodegenerative disease with occult onset and progressive development [8].”
BackgroundIncidence and prevalence of Alzheimer’s disease in China: a systematic review and meta-analysis
Ji, Q., Chen, J., Li, Y., Tao, E., & Zhan, Y. (2024) · European Journal of Epidemiology · doi:10.1007/s10654-024-01144-2 · Cited by 66
“AD primarily affects the medial temporal lobe and neocortical structures, leading to progressive neurodegeneration [1].”
Diagnosis and Treatment of Alzheimer’s Disease:
Bomasang-Layno, E., & Bronsther, R. (2021) · Delaware Journal of Public Health · doi:10.32481/djph.2021.09.009 · Cited by 75
The Molecular Effects of Environmental Enrichment on Alzheimer’s Disease
Liew, A. K. Y., Teo, C. H., & Soga, T. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03016-w · Cited by 62
“Finally, patients suffering from latestage AD will lose the ability to recognize individuals while also gradually losing control of their motor functions [5].”
BackgroundNovelties on Neuroinflammation in Alzheimer’s Disease–Focus on Gut and Oral Microbiota Involvement
Popescu, C., Munteanu, C., Anghelescu, A., Ciobanu, V., Spînu, A., Andone, I., Mandu, M., Bistriceanu, R., Băilă, M., Postoiu, R.-L., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011272 · Cited by 63
“Alzheimer’s disease (AD) is a progressive neurodegenerative disorder [1], primarily characterized by memory loss, cognitive decline, and behavioral changes [2].”
BackgroundVontell, R. T., de Rivero Vaccari, J. P., Sun, X., Gultekin, S. H., Bramlett, H. M., Dietrich, W. D., & Keane, R. W. (2023) · Brain Pathology · doi:10.1111/bpa.13142 · Cited by 57
“Anatomically, the hippocampus is affected early in the disease and then the neurodegeneration progresses throughout the cerebral cortex [1, 2].”
BackgroundNeurotrophins and Other Growth Factors in the Pathogenesis of Alzheimer’s Disease
Numakawa, T., & Kajihara, R. (2023) · Life · doi:10.3390/life13030647 · Cited by 66
“To further understand the relationship between physical exercise and the regulation of neurogenesis, detailed information concerning the contribution of BDNF (pro or mature forms) and its receptors (TrkB or p75NTR) is needed. Furthermore, it is well known that the release of myokines (from skeletal muscles), adipokine…”
ABCA7 deficiency causes neuronal dysregulation by altering mitochondrial lipid metabolism
Kawatani, K., Holm, M.-L., Starling, S. C., Martens, Y. A., Zhao, J., Lu, W., Ren, Y., Li, Z., Jiang, P., Jiang, Y., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02372-w · Cited by 53
“Accumulating evidence has shown the predominant contribution of genetic factors to AD onset and development [2].”
BackgroundRecent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56
“DMTs consist of three primary components: therapy, sick-Molecules ness, and modification [37,59].”
BackgroundInfluentialSelf-citationYan, X., Liu, H., Hong, Y.-X., Meng, T., Du, J., & Chang, C. (2022) · Journal of Neurogenetics · doi:10.1080/01677063.2022.2028784 · Cited by 57
“At present, there are only two classes of drugs approved for the treatment of AD, cholinesterase inhibitors and N-methyl D-aspartic acid antagonists (NMDA), which are only effective in treating AD symptoms but do not cure or prevent the disease (Breijyeh & Karaman, 2020).”
BackgroundНеганова, М. Е., Aleksandrova, Y. R., Sukocheva, O. A., & Klochkov, S. G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.06.011 · Cited by 58
Hajjo, R., Sabbah, D. A., Abusara, O. H., & Bawab, A. Q. A. (2022) · Diagnostics · doi:10.3390/diagnostics12122975 · Cited by 62
Alzheimer’s disease: a mini-review for the clinician
Madnani, R. S. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1178588 · Cited by 64
“Beyond these factors, a variety of lifestyle-associated elements such as diet, physical activity, history of brain injury, and cardiovascular health have been statistically correlated with late-onset dementia (4), but the connection between these factors and specific Alzheimer’s pathology is inconclusive and requires…”
BackgroundInfluentialA robust and clinically applicable deep learning model for early detection of Alzheimer's
Rana, M. M., Islam, M. M., Talukder, M. A., Uddin, M. A., Aryal, S., Alotaibi, N., Alyami, S. A., Hasan, K. F., & Moni, M. A. (2023) · IET Image Processing · doi:10.1049/ipr2.12910 · Cited by 62
Sun, T., Zhen, T., Harakandi, C. H., Wang, L., Guo, H., Chen, Y., & Sun, H. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116569 · Cited by 64
The Impact of Neurotransmitters on the Neurobiology of Neurodegenerative Diseases
Davis, S. E., Cirincione, A. B., Jiménez-Torres, A. C., & Zhu, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015340 · Cited by 61
“For instance, in AD patients, acetylcholine esterase inhibitors are used to increase acetyl choline (ACh) available for signaling [3].”
BackgroundMaitre, Y., Mahalli, R., Micheneau, P., Delpierre, A., Amador, G., & Denis, F. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182111157 · Cited by 61
“Treatments for AD are currently symptomatic, but research is targeting its pathological features, including Aβ peptides and tau protein [78].”
BackgroundBai, X., Bian, Z., & Zhang, M. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154582 · Cited by 58
Hydrogen Sulphide-Based Therapeutics for Neurological Conditions: Perspectives and Challenges
Sharif, A. H., Iqbal, M., Manhoosh, B., Gholampoor, N., Ma, D., Marwah, M. K., & Sanchez-Aranguren, L. C. (2023) · Neurochemical Research · doi:10.1007/s11064-023-03887-y · Cited by 57
“Oxidative stress, neuroinflammation and damage to cholinergic neurons are some of the pathophysiological changes that are involved in AD [71].”
BackgroundAkash, S., Aovi, F. I., Azad, A., Kumer, A., Chakma, U., Islam, M. R., Mukerjee, N., Rahman, M. M., Bayıl, İ., Rashid, S., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283271 · Cited by 54
Ferroptosis: underlying mechanisms and involvement in neurodegenerative diseases
Wang, Y., Li, H., He, Q., Zou, R., Cai, J., & Zhang, L. (2023) · APOPTOSIS · doi:10.1007/s10495-023-01902-9 · Cited by 59
“Currently, the global population of individuals diagnosed with AD stands at approximately 50 million, and it is predicted to reach 152 million by 2050 [47].”
Strong, C. E., Zhang, J., Carrasco, M., Kundu, S., Boutin, M. E., Vishwasrao, H. D., Liu, J., Medina, A., Chen, Y., Wilson, K. M., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05582-8 · Cited by 55
Phenolic Compounds of Therapeutic Interest in Neuroprotection
Nájera-Maldonado, J. M., Salazar, R., Fitz, P. Á., Quiroz, M. E. A., Flores‐Alfaro, E., Hernández‐Sotelo, D., Espinoza-Rojo, M., & Ramírez, M. (2024) · Journal of Xenobiotics · doi:10.3390/jox14010014 · Cited by 56
“…(NMDA) antagonists, which only alleviate For example, in the handling of AD, there are three classes of approved medications, cholinesterase enzyme inhibitors, and N-methyl D-aspartate (NMDA) antagonists, which only alleviate the symptoms of AD but do not cure or prevent the disease [19].”
BackgroundMunteanu, C., Onose, G., Rotariu, M., Poştaru, M., Turnea, M. A., & Galaction, A. (2024) · Biomedicines · doi:10.3390/biomedicines12122670 · Cited by 63
“…in gut microbiota, known as dysbiosis, can lead to abnormal H 2 S production and the subsequent worsening of neuroinflammatory processes (Figure 1) [8]. dysbiosis, can lead to abnormal H 2 S metabolites such as short-chain fa tt y acids (SCFAs), tryptophan metabolites, and hydrogen sul fi de (H 2…”
Lipid nanoparticle (LNP) mediated mRNA delivery in neurodegenerative diseases
Moosavi, S. G., Rahiman, N., Jaafari, M. R., & Arabi, L. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113641 · Cited by 61
Hu, X. Y., Zhang, J., Qiu, Y., & Liu, Z. (2021) · Psychogeriatrics · doi:10.1111/psyg.12743 · Cited by 58
The role of microglia in Alzheimer's disease and progress of treatment
Guan, Y., Zhang, L., Wang, S., Deng, Y., Zhou, H., Chen, D., & Zhang, L. (2022) · Ibrain · doi:10.1002/ibra.12023 · Cited by 59
“which will place a burden on the society and families.(1) AD is characterized by the deposition of β‐amyloid peptide (Abeta, Aβ) and Tau protein, and the progressive loss of neurons that causes dementia.”
The promising role of natural products in Alzheimer's disease
da Rosa, M. M., de Amorim, L. C., Alves, J. V. D. O., Aguiar, I. F. D. S., Oliveira, F. G. D. S., da Silva, M. V., & dos Santos, M. T. C. (2022) · Brain Disorders · doi:10.1016/j.dscb.2022.100049 · Cited by 56
Domínguez-Fernández, C., Egiguren-Ortiz, J., Razquin, J., Gómez-Galán, M., Heras-García, L. D. L., Paredes-Rodriguez, E., Astigarraga, E., Miguélez, C., & Barreda‐Gómez, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043321 · Cited by 60
Alexander, C., Parsaee, A., & Vasefi, M. (2023) · Biology · doi:10.3390/biology12111453 · Cited by 62
“AD could affect 152 million individuals by 2050 [1].”
BackgroundXu, S., Cao, H., Yang, R.-H., Xu, R.-X., Zhu, X., Ma, W., Liu, X., Yan, X., & Fu, P. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155483 · Cited by 55
Khodadadi, H., Salles, É. L., Jarrahi, A., Costigliola, V., Khan, M. B., Yu, J. C.-K., Morgan, J. C., Hess, D. C., Vaibhav, K., Dhandapani, K. M., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210026 · Cited by 52
“E-mail:bbaban@augusta.edu. decline [1, 2], placing a massive emotional and economic burden on society.”
Anti-Inflammatory Effects of Flavonoids in Common Neurological Disorders Associated with Aging
Martínez‐Coria, H., Arrieta‐Cruz, I., Juárez, R. G., & López-Valdés, H. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054297 · Cited by 53
Cruz, E. Y. H., Eugenio-Pérez, D., Ramírez-Magaña, K. J., & Pedraza‐Chaverrí, J. (2023) · ACS Omega · doi:10.1021/acsomega.2c07025 · Cited by 52
Federated Explainable AI-Based Alzheimer’s Disease Prediction With Multimodal Data
Jahan, S., Adib, M. R. S., Huda, S. M., Rahman, M. S., Kaiser, M. S., Hosen, A. S. M. S., Ghimire, D., & Park, M. J. (2025) · IEEE Access · doi:10.1109/access.2025.3547343 · Cited by 62
“These symptoms include mood fluctuations, the start of depression, trouble recalling and concentrating on things, and navigating time and location [8].”
Das, S., Goossens, J., Jacobs, D., Dewit, N., Pijnenburg, Y. A. L., In ‘t Veld, S. G. J. G., Teunissen, C. E., & Vanmechelen, E. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01212-x · Cited by 50
“The pathological signature of AD is amyloid beta (Aβ) plaque accumulation in the neocortex of the brain, while in FTD, there is degeneration of the frontal and temporal lobes, including in para-limbic areas [4, 5].”
BackgroundGeorge, N., Sabahi, B. A., AbuKhader, M., Balushi, K. A. A., Akhtar, M. J., & Khan, S. A. (2022) · Journal of King Saud University - Science · doi:10.1016/j.jksus.2022.101977 · Cited by 53
Chaperones—A New Class of Potential Therapeutic Targets in Alzheimer’s Disease
Batko, J., Antosz, K., Miśków, W., Pszczołowska, M., Walczak, K., & Leszek, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063401 · Cited by 51
“Recent discoveries point to the significant impact of the dysfunction of chosen proteins, chaperones, and co-chaperones on AD pathogenesis [3].”
BackgroundAzmal, M., Hossen, M. S., Shohan, M. N. H., Taqui, R., Malik, A., & Ghosh, A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0304490 · Cited by 59
Moiniafshari, K., Zanut, A., Tapparo, A., Pastore, P., Bogialli, S., & Monikh, F. A. (2025) · Environmental Science Nano · doi:10.1039/d4en01017e · Cited by 62
“79 AD is characterized by the accumulation of amyloid-beta (A β ) plaques in the brain and misfolded protein inside neurons 80 MNPs have recently been studied for their potential role in exacerbating neurodegenerative conditions such as AD.”
Targeting of Extracellular Vesicle-Based Therapeutics to the Brain
Williams, A., Branscome, H., Kashanchi, F., & Batrakova, E. V. (2025) · Cells · doi:10.3390/cells14070548 · Cited by 51
Kurhaluk, N., Kamiński, P., Bilski, R., Kołodziejska, R., Woźniak, A., & Ткаченко, Г. М. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083658 · Cited by 58
“It is characterised by the accumulation of amyloid beta (A β ) plaques and tau tangles in the brain, accompanied by neuroinflammation and neuronal cell death [201].”
Xu, H., Zhou, Q., Liu, B., Cheng, K., Chen, F., & Wang, M. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c04049 · Cited by 56
Neurodevelopmental Clues to Neurodegeneration
Schor, N. F., & Bianchi, D. W. (2021) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2021.07.012 · Cited by 52
Histone deacetylase-6 modulates Tau function in Alzheimer's disease
Qureshi, T., & Chinnathambi, S. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119275 · Cited by 56
Cerdá-Bernad, D., Costa, L., Serra, T., Bronze, M. R., Valero‐Cases, E., Pérez‐Llamas, F., Castillo, M. E. C., Arnao, M. B., Tomás-Barberán, F. A., García-Villalba, R., et al. (2022) · Nutrients · doi:10.3390/nu14245368 · Cited by 52
“At present, there are not many drugs to treat this disease, and new therapies and natural compounds are being investigated [81].”
BackgroundNon-Enzymatic Antioxidants against Alzheimer’s Disease: Prevention, Diagnosis and Therapy
Varesi, A., Campagnoli, L. I. M., Carrara, A., Pola, I., Floris, E., Ricevuti, G., Chirumbolo, S., & Pascale, A. (2023) · Antioxidants · doi:10.3390/antiox12010180 · Cited by 53
“Molecularly, AD presents a multifactorial etiology, in which genetic and environmental factors contribute to the formation of senile amyloid plaques, composed of amyloid beta (Aβ) fibrils, and intracellular neurofibrillary tangles (primarily characterized by the abnormal accumulation of the microtubule-associated tau…”
BackgroundRole of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders
Guo, Z.-H., Khattak, S., Rauf, M. A., Ansari, M. A., Alomary, M. N., Razak, S., Yang, C., Wu, D., & Ji, X. (2023) · Molecules · doi:10.3390/molecules28031283 · Cited by 59
The Nerve Growth Factor Receptor (NGFR/p75NTR): A Major Player in Alzheimer’s Disease
Bruno, F., Abondio, P., Montesanto, A., Luiselli, D., Bruni, A. C., & Maletta, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043200 · Cited by 57
“Alzheimer’s disease (AD) represents the most prevalent type of dementia in elderly people [1], primarily characterized by brain accumulation of beta-amyloid (Aβ) peptide in the extracellular space (amyloid plaques) and intracellular deposits of paired helical filaments (PHF), mainly formed by the hyperphosphorylated f…”
BackgroundRecent progress of nanomedicine in the treatment of Alzheimer’s disease
Hu, L., Tao, Y., Jiang, Y., & Qin, F. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1228679 · Cited by 52
“The number of studies examining the cause and progression of AD has never stopped, since the German neurologist and psychiatrist Alois Alzheimer initially described the condition in 1907 (Breijyeh and Karaman, 2020).”
BackgroundInfluentialAutophagy-lysosomal pathway impairment and cathepsin dysregulation in Alzheimer’s disease
Mançano, A. S. F., Pina, J. G., Froes, B. R., & Sciani, J. M. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1490275 · Cited by 52
Fołta, J., Rzepka, Z., & Wrześniok, D. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115177 · Cited by 56
“…treatment of Alzheimer’s disease; i /inhibitors of the enzyme cholinesterase, i.e., donepezil, rivastigmine, or galantamine, and ii /N-methyl-D-aspartate antagonists, i.e., memantine, which are only effective in treating the symptoms of the disease but do not cure or prevent the disease [88,114].”
Ischemia as a common trigger for Alzheimer’s disease
Elman-Shina, K., & Efrati, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1012779 · Cited by 48
Cognitive tasks propagate the neural entrainment in response to a visual 40 Hz stimulation in humans
Khachatryan, E., Wittevrongel, B., Reinartz, M., Dauwe, I., Carrette, E., Meurs, A., Roost, D. V., Boon, P., & Hulle, M. M. V. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1010765 · Cited by 49
“Several pharmaceutical therapies aimed at improving amyloid clearance have been developed but reported little success (Breijyeh and Karaman, 2020).”
BackgroundApplication of Marine Natural Products against Alzheimer’s Disease: Past, Present and Future
Hu, D., Jin, Y., Hou, X., Zhu, Y., Chen, D., Tai, J., Chen, Q., Shi, C., Ye, J., Wu, M., et al. (2023) · Marine Drugs · doi:10.3390/md21010043 · Cited by 53
“Directly combine with Aβ to reduce Aβ in brain deposition [43] tago ist of t e [37]”
BackgroundSmall-molecule theranostics in Alzheimer's disease
Sarabia‐Vallejo, Á., López‐Alvarado, P., & Menéndez, J. C. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115382 · Cited by 52
Morphological and Molecular Profiling of Amyloid-β Species in Alzheimer’s Pathogenesis
Almeida, Z. L., Vaz, D. C., & Brito, R. M. M. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04543-4 · Cited by 52
“Age is the main risk factor [8], but individuals primary domains/regions: the N-terminal domain (red), the proline-rich domain (green), the repeat domain (RD) or microtubule-binding domain (blue), and the C-terminal region (gray).”
Yaghmaei, E., Lu, H., Ehwerhemuepha, L., Zheng, J., Danioko, S., Rezaie, A., Sajjadi, S. A., & Rakovski, C. (2024) · Communications Medicine · doi:10.1038/s43856-024-00527-6 · Cited by 47
The dopaminergic system and Alzheimer’s disease
Zhang, Y., Liang, Y., & Gu, Y. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00230 · Cited by 51
“The etiology of AD is complex and involves both environmental and genetic factors (Breijyeh and Karaman, 2020).”
Dehghani, S., Ocakcı, O., Hatipoglu, P. T., Özalp, V. C., & Tevlek, A. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04825-5 · Cited by 55
Malta, S. M., Batista, L. L., Silva, H. C. G., Franco, R. R., Silva, M. H., Rodrigues, T. S., Correia, L. I. V., Martins, M. M., Venturini, G., Espíndola, F. S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-15297-1 · Cited by 54
Dendrimers in Alzheimer’s Disease: Recent Approaches in Multi-Targeting Strategies
Arbez‐Gindre, C., Steele, B. R., & Micha‐Screttas, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030898 · Cited by 49
“Apart from aging, other risk factors include sex, diabetes, hypertension, obesity, hypercholesterolemia and traumatic brain injury [1,2].”
BackgroundMonoclonal Antibody Therapy in Alzheimer’s Disease
Neațu, M., Covaliu, A., Ioniță, I., Jugurt, A., Davidescu, E. I., & Popescu, B. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010060 · Cited by 48
“Presently, approximately 35.6 million individuals worldwide are afflicted with dementia, with a yearly incidence of 7.7 million novel cases [4,5].”
BackgroundInfluentialA Survey on Computational Methods in Drug Discovery for Neurodegenerative Diseases
Vicidomini, C., Fontanella, F., D’Alessandro, T., & Roviello, G. N. (2024) · Biomolecules · doi:10.3390/biom14101330 · Cited by 50
“As for sporadic AD, the primary risk factor is thought to be ageing [21,22], but since it represents a complex disorder, other risk factors have also been identified, including traumatic brain injury, female sex, environmental pollution, depression, social isolation, low academic achievement,…”
Background
Metadata
- Authors
- Breijyeh, Z., & Karaman, R.
- Affiliations
- Al-Quds University (PS)
- Corresponding author
- Karaman, Rafik
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-12-08
- Volume
- 25
- Issue
- 24
- Pages
- 5789
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7764106
- OpenAlex
- W3112948680
- Cited by
- 2,789
- References
- 149
- Citations by year
- 2026: 418 · 2025: 708 · 2024: 733 · 2023: 541 · 2022: 310 · 2021: 79
- FWCI
- 29.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, dementia, cholinergic hypothesis, amyloid hypothesis, risk factors, cholinesterase inhibitors, NMDA receptor antagonists, tau protein, amyloid-beta, neuroinflammation, oxidative stress, disease-modifying therapy, molecular chaperones, natural compounds, drug development
- MeSH terms
- Alzheimer Disease, Animals, Disease Susceptibility, Humans, Risk Factors, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Risk Assessment, Disease Management, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.